BACKGROUND: The circumferential resection margin (CRM) is highly prognostic for local recurrence in rectal cancer surgery without neoadjuvant treatment. However, its significance in the setting of long-course neoadjuvant chemoradiotherapy (nCRT) is not well defined. METHODS: Review of a single institution's prospectively maintained database from 1998 to 2007 identified 563 patients with locally advanced rectal cancer (T3/T4 and/or N1) receiving nCRT, followed after 6 weeks by total mesorectal excision (TME). Kaplan-Meier, Cox regression, and competing risk analysis were performed. RESULTS: The authors noted that 75 % of all patients had stage III disease as determined by endorectal ultrasound (ERUS) and/or magnetic resonance imaging (MRI). With median follow-up of 39 months after resection, local and distant relapse were noted in 12 (2.1 %) and 98 (17.4 %) patients, respectively. On competing risk analysis, the optimal cutoff point of CRM was 1 mm for local recurrence and 2 mm for distant metastasis. Factors independently associated with local recurrence included CRM ≤1 mm, and high-grade tumor (p = 0.012 and 0.007, respectively). CRM ≤2 mm, as well as pathological, nodal, and overall tumor stage are also significant independent risk factors for distant metastasis (p = 0.025, 0.010, and <0.001, respectively). CONCLUSION: In this dataset of locally advanced rectal cancer treated with nCRT followed by TME, CRM ≤1 mm is an independent risk factor for local recurrence and is considered a positive margin. CRM ≤2 mm was associated with distant recurrence, independent of pathological tumor and nodal stage.
BACKGROUND: The circumferential resection margin (CRM) is highly prognostic for local recurrence in rectal cancer surgery without neoadjuvant treatment. However, its significance in the setting of long-course neoadjuvant chemoradiotherapy (nCRT) is not well defined. METHODS: Review of a single institution's prospectively maintained database from 1998 to 2007 identified 563 patients with locally advanced rectal cancer (T3/T4 and/or N1) receiving nCRT, followed after 6 weeks by total mesorectal excision (TME). Kaplan-Meier, Cox regression, and competing risk analysis were performed. RESULTS: The authors noted that 75 % of all patients had stage III disease as determined by endorectal ultrasound (ERUS) and/or magnetic resonance imaging (MRI). With median follow-up of 39 months after resection, local and distant relapse were noted in 12 (2.1 %) and 98 (17.4 %) patients, respectively. On competing risk analysis, the optimal cutoff point of CRM was 1 mm for local recurrence and 2 mm for distant metastasis. Factors independently associated with local recurrence included CRM ≤1 mm, and high-grade tumor (p = 0.012 and 0.007, respectively). CRM ≤2 mm, as well as pathological, nodal, and overall tumor stage are also significant independent risk factors for distant metastasis (p = 0.025, 0.010, and <0.001, respectively). CONCLUSION: In this dataset of locally advanced rectal cancer treated with nCRT followed by TME, CRM ≤1 mm is an independent risk factor for local recurrence and is considered a positive margin. CRM ≤2 mm was associated with distant recurrence, independent of pathological tumor and nodal stage.
Authors: D F de Haas-Kock; C G Baeten; J J Jager; J A Langendijk; L J Schouten; A Volovics; J W Arends Journal: Br J Surg Date: 1996-06 Impact factor: 6.939
Authors: Ingrid S Martijnse; Ralph L Dudink; Nicholas P West; Dareczka Wasowicz; Grard A Nieuwenhuijzen; Ineke van Lijnschoten; Hendrik Martijn; Valery E Lemmens; Cornelis J van de Velde; Iris D Nagtegaal; Phil Quirke; Harm J Rutten Journal: Ann Surg Oncol Date: 2011-08-23 Impact factor: 5.344
Authors: Iris D Nagtegaal; Corrie A M Marijnen; Elma Klein Kranenbarg; Cornelis J H van de Velde; J Han J M van Krieken Journal: Am J Surg Pathol Date: 2002-03 Impact factor: 6.394
Authors: Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard B Saltz; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; Martin R Weiser Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: K Bujko; M P Nowacki; A Nasierowska-Guttmejer; W Michalski; M Bebenek; M Pudełko; M Kryj; J Oledzki; J Szmeja; J Słuszniak; K Serkies; J Kładny; M Pamucka; P Kukołowicz Journal: Radiother Oncol Date: 2004-07 Impact factor: 6.280
Authors: Nicholas P West; Paul J Finan; Claes Anderin; Johan Lindholm; Torbjorn Holm; Philip Quirke Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: I J Adam; M O Mohamdee; I G Martin; N Scott; P J Finan; D Johnston; M F Dixon; P Quirke Journal: Lancet Date: 1994-09-10 Impact factor: 79.321
Authors: Marcus Kiehlmann; Klaus Weber; Jonas Göhl; Rainer Fietkau; Abbas Agaimy; Werner Hohenberger; Susanne Merkel Journal: Int J Colorectal Dis Date: 2015-10-24 Impact factor: 2.571
Authors: Fabian A Holman; Michael G Haddock; Leonard L Gunderson; Miranda Kusters; Grard A P Nieuwenhuijzen; Hetty A van den Berg; Heidi Nelson; Harm J T Rutten Journal: J Gastrointest Oncol Date: 2016-12